John Coombs

The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double‐blind, placebo‐controlled phase IIa trial of three dosage levels of CP‐690,550 versus placebo

Joel M. Kremer, Bradley J. Bloom, Ferdinand C. Breedveld et al. · Arthritis & Rheumatism · 2009 · 541 citations

Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial

John Coombs, Bradley J. Bloom, F. C. Breedveld et al. · Annals of the Rheumatic Diseases · 2009 · 147 citations

Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients

Eric Q. Wu, Scott J. Johnson, Nicolas Beaulieu et al. · Current Medical Research and Opinion · 2009 · 129 citations

Compliance from Self-Reported versus Pharmacy Claims Data with Metered-Dose Inhalers

Steven R. Erickson, John Coombs, Duane M. Kirking et al. · Annals of Pharmacotherapy · 2001 · 116 citations

Celecoxib is efficacious and well tolerated in treating signs and symptoms of ankylosing spondylitis.

André Barkhuizen, Serge Steinfeld, Jeffery Robbins et al. · PubMed · 2006 · 75 citations